News & Publications

Celloram successfully closes its 8M Seed Series Round

Celloram successfully closed its $8M Seed Series Round, securing funds to advance its mission of developing safer and more effective treatments for cancer, immune and metabolic disorders. Seed Series investors include MedPacto Inc., Theragen Etex, and Winvest, among others.

Celloram’s research pipelines focus on both innovative cell therapies and novel small molecule therapeutics, with primary indications including difficult-to-treat triple negative breast cancer (TNBC) and graft-versus-host disease (GVHD). The Seed Series funds will allow Celloram to expand its research team and facilities and provide continued support of the development of novel therapies for these critical disease indications.

Analyzing the Metabolic Phenotype of Bone Marrow-Derived Dendritic Cells by Assessing Their Oxygen Consumption and Extracellular Acidification
Celloram is awarded $0.2M DOD Grant to improve Post-Trauma-Induced Osteoarthritis